Hodgkin's disease - The role of radiation therapy in advanced disease

Annals of Oncology

Volumn 7, Issue SUPPL. 4, 1996, Pages

  Hoppe, R T ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced stages; Hodgkin's disease; Radiation therapy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; ETOPOSIDE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL; RADIATION DOSE; WHOLE BODY RADIATION;

EID: 0029836645     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_4.S99     Document Type: Conference Paper

References (22)

1. Young RC, Canellos GP, Chabner BA et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978; 42:1001-7.
2. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 1966; 20:1221-4.
3. Prosnitz LR, Farber LR, Kapp DS et al. Combined modality therapy for advanced Hodgkin's disease: 15-Year follow-up data. J Clin Oncol 1988; 6:603-12.
4. Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985; 11:5-22.
5. Somers R, Henry-Amar M, Meerwoldt JH, Carde P (eds). Treatment Strategy in Hodgkin's Disease. Colloque Inserin No. 196. London, Paris: Inserm/John Libby Eurotext 1990.
6. Diehl V, Pfreundschuh M, Loffler M et al. Chemotherapy versus involved-field (IF) radiotherapy for consolidation of remission achieved with three double cycles of cyclophosphamide, vincristine, procarbazine, prednisone (COPP) and doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) for stages 111B/TV Hodgkin's disease: A randomized trial of the German Hodgkin Study Group. Proc ASCO 1990; 1057:273 (Abstr).
7. Fabian CJ, Mansfield CM, Dahlberg S et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. A Southwest Oncology Group Randomized Study. Ann Intern Med 1994; 120:903.
8. Raemaekers J, Burgers J, Henry-Amar M et al. Involved field radiotherapy for patients in partial remission after MOPP/ ABV chemotherapy in stage ni/IV Hodgkin's disease: Results from the EORTC Lymphoma Cooperative Group and Groupe Pierre-at-Marie-Curie Phase III Trial (protocol 20884). Proc. 3rd ISHL, Cologne, Germany 1995 (Abstr).
9. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295306.
10. Fabian C, Dahlberg S, Miller T et al. Effiacy of low-dose involved field (LDIF) XRT in producing and maintaining CR following PR induction with MOP-BAP chemotherapy in Hodgkin's disease, results of Southwest Oncology Group Study 7808. Proc ASCO 1989; 987:253.
11. Hoppe RT, Portlock CS, Glatstein E et al. Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease. Cancer 1979; 43:472-81.
12. Bartlett NL, Rosenberg SA, Hoppe RT et al. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report. J Clin Oncol 1995; 13:1080-8.
13. Roach M, Brophy N, Cox R et al. Prognostic factors for patients relapsing after radiation therapy for early stage Hodgkin's disease. J Clin Oncol 1990; 8:623-9.
14. Uematsu M, Tarbell NJ, Silver B et al. Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin's disease in relapse after initial combination chemotherapy. Cancer 1993; 72:207-12.
15. Lohri A, Connors J. Identification of risk factors in patients treated for first relapse of Hodgkin's disease. Leuk Lymph 1994; 15:189-200.
16. O'Brien PC, Parnis FX. Salvage radiotherapy following chemotherapy failure in Hodgkin's disease - what is its role? Acta Oncol 1995; 34:99-104.
17. Pezner RD, Nademence A, Forman SJ. High-dose therapy and autologous bone marrow transplantation for Hodgkin's disease patients with relapses potentially treatable by radical radiation therapy. Int J Radiat Oncol Phys 1995; 33:189-94.
18. Horning SJ, Chao NJ, Negrin RS et al. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data. Ann Oncol 1991; 2:47-50.
19. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11:1062-70.
20. Mundt AJ, Sibley KG, Williams S et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/ refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1994; 31 (Suppl 1): 16 (Abstr).
21. Pezner RD, Nademanee A, Niland JC et al. Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 1995; 34: 23-9.
22. Poen JC, Hoppe RT, Horning SJ, Blume KG. High-dose therapy and autologous bone marrow transplantation for relapsed/ refractory Hodgkin's disease: The impact of total body irradiation and involved field radiotherapy. ECCO, Paris, November 1995.